The prospective, open, multi-center clinical study of Apatinib(Aitan) in non-first-line treating patient with recurrent/metastatic head and neck squamous cell carcinoma

Trial Profile

The prospective, open, multi-center clinical study of Apatinib(Aitan) in non-first-line treating patient with recurrent/metastatic head and neck squamous cell carcinoma

Not yet recruiting
Phase of Trial: Phase IV

Latest Information Update: 23 Jul 2016

At a glance

  • Drugs Apatinib (Primary)
  • Indications Head and neck cancer; Squamous cell cancer
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 23 Jul 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top